House Bill 3348
115th Congress(2017-2018)
Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act
Introduced
Introduced in House on Jul 20, 2017
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
3348
Congress
115
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
No House votes have been held for this bill.
Summary
Adding Middle East Respiratory Syndrome to the FDA Priority Review Voucher Program Act
This bill amends the Federal Food, Drug, and Cosmetic Act to include Middle East respiratory syndrome under the priority review voucher program for tropical diseases, which awards a voucher to the sponsor of a new drug or biological product that is approved to prevent or treat a tropical disease. (A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.)July 20, 2017
07/20/2017
Referred to the House Committee on Energy and Commerce.
07/20/2017
Introduced in House
Public Record
Record Updated
Jan 11, 2023 1:37:22 PM